November 2025 in “Skin Appendage Disorders” This study reviewed evidence on biologic drugs targeting immune cells for alopecia areata, finding mixed results: some achieved case-level hair regrowth, but controlled trials often showed limited efficacy.
49 citations
,
August 2022 in “Frontiers in Immunology” This paper discusses the evolving understanding of psoriasis pathogenesis with no new clinical findings; the authors highlight the role of T-cell plasticity and regulatory cells, calling for further clinical applications using single-cell technologies.
March 2026 in “Skin Appendage Disorders” This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.
May 2022 in “Голова и шея.” This report describes a case of a patient with metastatic renal cell carcinoma who developed a psoriasiform skin lesion while undergoing immune checkpoint inhibitor therapy.
3 citations
,
October 2018 in “Journal of Mind and Medical Sciences” This study highlights that biological therapy, which stimulates the immune system through various methods like cytokine injections and immune checkpoint inhibition, shows promise for treating melanoma based on laboratory and clinical studies.